Trial Profile
A clinical study of Glecaprevir/Pibrentasvir (G/P) and Sofosbuvir (SOF) in Hepatitis C virus infection difficult to treat patients including DAA failure patients
Status:
Recruiting
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 18 Jul 2018
Price :
$35
*
At a glance
- Drugs Glecaprevir/pibrentasvir (Primary) ; Sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Expanded access; Therapeutic Use
- 05 Jun 2018 SVR12 data will be available for all patients in April 2018.
- 05 Jun 2018 Results presented at the Digestive Disease Week 2018
- 15 May 2018 New trial record